MEDICAL THERAPY FOR SECONDARY PREVENTION OF STROKE

REFERENCES

• Bamford J., Sandercock P., Dennis M. A Prospective Study of Acute Cerebrovascular Disease in the Community, the OCSP 1981–1986. J. Neurol. Neurosurg. Psychiatry 1988; 51: 1373–1380, et al.
   PubMed Web of Science ®Google Scholar
• Thorvaldsen P., Asplund K., Kualasmaa K., Rajakangas A-M. for the WHO MONICA Project. Stroke Incidence, Case Fatality, and Mortality in the WHO MONICA Project. Stroke 1995; 26: 361–367
   PubMed Web of Science ®Google Scholar
• Hankey G. I., Jamrozik K., Broadhurst R. J. Long-Term Risk of Recurrent Stroke in the Perth Community Stroke Study. Stroke 1998; 29: 2491–2500, et al.
   PubMed Web of Science ®Google Scholar
• Wilterdink H., Easton J. D. Vascular Event Rates in Patients with Atherosclerotic Cerebrovascular Disease. Arch. Neurol. 1992; 49: 857–863
   PubMed Web of Science ®Google Scholar
• Antiplatelet Trialist Collaboration. Collaborative Overview of Randomised Trials of Antiplatelet Therapy. BMJ 1994; 308: 81–106
   PubMed Web of Science ®Google Scholar
• Lai S. M., Alter M., Friday G., Sobel E. A Multifactorial Analysis of Risk Factors for Recurrence of Ischemic Stroke. Stroke 1994; 25: 958–962
   PubMed Web of Science ®Google Scholar
• Hier D. B., Foulkes M. A., Swiontoniowski M. Stroke Recurrence Within 2 Years After Ischemic Infarction. STROKE 1991; 22: 155–161, et al.
   PubMed Web of Science ®Google Scholar
• UK. TIA. Study Group. The UK TIA Aspirin Trial, Final Results. J. Neurol. Neurosurg. Psychiatry 1991; 54: 1044–1054
   PubMed Web of Science ®Google Scholar
• SHEP. Cooperative Research Group. Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons with Isolated Systolic Hypertension, Final Results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255–3264
   PubMed Web of Science ®Google Scholar
• MacMahon S. Blood Pressure and Prevention of Stroke. J. Hypertens. 1996; 14(6)S39–S46
   Google Scholar
• The INDIANA. (Individual Data Analysis of Antihypertensive Intervention trials) Project Collaborators. Effect of Antihypertensive Treatment in Patients Having Already Suffered from Stroke. Stroke 1997; 28: 2557–2562
   PubMed Web of Science ®Google Scholar
• MOSES. Morbidity and Mortality After Stroke. Eposartan vs. Nitrendipine for Secondary Stroke Prevention. Stroke 1999; 30: 2258
   Google Scholar
• PROGRESS (Perindopril Protection Against Recurrent Stroke Study). Stroke 1999; 30: 2259
   Google Scholar
• Stroke Hypertension and Recurrence in Kyushu. Stroke 1999; 30: 2260
   Google Scholar
• Wolf P. A., Abbott R. D., Kannel W. B. Atrial Fibrillation, a Major Contributor to Stroke in the Elderly. The Framingham Study. Arch. Int. Med. 1987; 147: 1561–1564
   PubMed Web of Science ®Google Scholar
• Sandercock P., Bamford J., Dennis M. Atrial Fibrillation and Stroke, Prevalence in Different Types of Stroke and Influence on Early and Long Term Prognosis. BMJ 1992; 305: 1460–1465, et al.
   PubMed Web of Science ®Google Scholar
• EAFT (European Atrial Fibrillation Trial) Study Group. Secondary Prevention in Non-Rheumatic Atrial Fibrillation After TIA or Minor Stroke. Lancet 1993; 342: 1255–1262
   PubMed Web of Science ®Google Scholar
• Ceriello A. Coagulation of Activation in Diabetes Mellitus, the Role of Hyperglycemia and Therapeutic Prospects. Diabetologia. 1993; 36: 1119–1125
   PubMed Web of Science ®Google Scholar
• Stout R. W. Hyperglycemia and Stroke. Q. J. Med. 1989; 73: 997–1004
   PubMedGoogle Scholar
• Sacco R. L. Risk Factors and Outcome for Ischemic Stroke. Neurology 1995; 45(1)S10–S14
   PubMedGoogle Scholar
• Prospective Studies Collaboration. Cholesterol, Diastolic Blood Pressure, and Stroke. 13,000 Strokes in 450,000 People in 45 Prospective Studies. Lancet 1995; 346: 1647–1653
   PubMed Web of Science ®Google Scholar
• Herbert P. R., Graziano J. H., Cham K. S., Hennekens C. H. Cholesterol Lowering with Statins Drugs, Risk of Stroke, and Total Mortality. An Overview of Randomised Trials. JAMA 1997; 278: 319–321
   Google Scholar
• Bucher H. C., Griffith L. E., Guyatt G. H. Effect of HMGCoA Reductase Inhibitors on Stroke, a Meta-Analysis of Randomised, Controlled Trials. Ann. Intern. Med. 1998; 128: 89–95
   PubMed Web of Science ®Google Scholar
• The Long-Term Intervention with Pravastin in Ischemic Disease (LIPID) Study Group. Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Level. N. Engl. J. Med. 1998; 339: 1349–1357
   PubMed Web of Science ®Google Scholar
• Plehn J. F., Davis B. R., Sacks F. M. For the CARE. Investigators. Reduction of Stroke Incidence After Myocardial Infarction with Pravastatin. The Cholesterol and Recurrent Events (CARE) Study. Circulation 1999; 99: 216–223, et al.
   PubMed Web of Science ®Google Scholar
• Hess D. C., Demchuk A. M., Brass L. M., Yatsu F. M. HMG-CoA Reductase Inhibitors (Statins), a Promising Approach to Stroke Prevention. Neurology 2000; 54(4)790–796
   PubMed Web of Science ®Google Scholar
• Cattaneo M. Hyperhomocysteinemia, Atherosclerosis and Thrombosis. Thromb. Haemost. 1999; 81: 165–176
   PubMed Web of Science ®Google Scholar
• VITATOPS (Vitamins to Prevent Stroke). Stroke 1999; 30: 2260
   Google Scholar
• VISP (Vitamin Intervention for Stroke Prevention). Stroke 1999; 30: 2260
   Google Scholar
• Algra A., van Gijn J. Aspirin at Any Dose Above 30 mg Offers Only Modest Protection After Cerebral Ischemia. J. Neurol. Neurosurg. Psychiatry 1996; 60: 197–199
   PubMed Web of Science ®Google Scholar
• Dippel D. W. The Results of CAPRIE, IST and CAST. Thromb. Res. 1998; 92(1)S13–S16
   PubMed Web of Science ®Google Scholar
• Grotemeyer K. H., Scharafinski H., Husstedt I. W. Two Year Follow-Up of Aspirin Responders and Non-responders, a Pilot Study Including 180 Post-Stroke Patients. Thromb. Res. 1993; 71: 397–403
   PubMed Web of Science ®Google Scholar
• Helgason C. M., Bolin K. M., Hoff J. A. Development of Aspirin Resistance in Persons with Previous Ischemic Stroke. Stroke 1994; 25: 2331–2336, et al.
   PubMed Web of Science ®Google Scholar
• Gent M., Blakely J. A., Easton J. D. The Canadian American Ticlopidine Study (CATS) in Thromboembolic Stroke. Lancet 1989; 1: 1215–1220, et al.
   PubMed Web of Science ®Google Scholar
• Hass W. K., Easton J. D., Adams H. P. A Randomised Trial Comparing Ticlopidine Hydrochloride with Aspirin for the Prevention of Stroke in High-Risk Patients. Ticlopidine Aspirin Stroke Study Group. N. Engl. J. Med. 1989; 321: 501–507, et al.
   PubMed Web of Science ®Google Scholar
• CAPRIE. A Randomised, Blinded Trial of Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events. Lancet 1996; 348: 1329–1339
   PubMed Web of Science ®Google Scholar
• Diener H., Cunha L., Forbes C. Dipyridamole and Acetylsalicylic in the Secondary Prevention of Stroke. J. Neurol. Sci. 1996; 143: 1–13, et al.
   PubMed Web of Science ®Google Scholar
• ESPRIT (European and Australian Stroke Prevention in Reversible Ischemia Trial). Anticoagulants vs. Aspirin and the Combination Aspirin and Dipyridamole vs Aspirin Only in Patients with TIAs or Non Disabling Ischemic Stroke. Stroke 1999; 30: 487
   PubMedGoogle Scholar
• Triflusal vs Aspirin in Secondary Prevention of Cerebral Infarction, TACIP Study (Triflusal, Aspirin, Cerebral Infarction Prevention). Stroke 1997; 28: 351
   Google Scholar
• Atrial Fibrillation Investigators. Risk Factors for Stroke and Efficacy of Antithrombotic Therapy in Atrial Fibrillation. Analysis of Pooled Data from Five Randomised Controlled Trials. Arch. Intern. Med. 1994; 343: 687–691
   Google Scholar
• Stroke Prevention in Atrial Fibrillation III Randomized Clinical Trial. Adjusted Dose Warfarin vs Low-Intensity, Fixed Dose Warfarine Plus Aspirin for High-Risk Patients with Atrial Fibrillation. Lancet 1996; 348: 633–638
   PubMed Web of Science ®Google Scholar
• Yamaguchi T. Optimal Intensity of Warfarin Therapy for Secondary Prevention in Patient with NVAF, a Multicenter, Prospective, Randomised Trial. Stroke 2000; 31(4)817–821
   PubMed Web of Science ®Google Scholar
• Gorter J. W. Major Bleeding During OAC After Cerebral Ischemia, Patterns and Risk Factors. Neurology 1999; 53(6)1319–1327
   PubMed Web of Science ®Google Scholar